CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01026792
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:51.147226+00:00
Published At: 2015-09-10T00:00:00+00:00
Record Updated At: 2015-09-10
Results Posted At: 2015-09-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Recurrent Cervical Carcinoma", "Stage IIIA Cervical Cancer", "Stage IIIB Cervical Cancer", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-09-10"
protocolSection.identificationModule.nctId: "NCT01026792"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-09-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.